Gainers
- Precigen PGEN inventory elevated by 61.6% to $2.99 throughout Friday’s pre-market session. The corporate’s market cap stands at $551.2 million. As per the information, the Q2 earnings report got here out 3 days in the past.
- Co-Diagnostics CODX shares moved upwards by 53.95% to $0.41. The corporate’s market cap stands at $8.9 million. As per the press launch, Q2 earnings got here out yesterday.
- Plus Therapeutics PSTV shares moved upwards by 15.82% to $0.63. The corporate’s market cap stands at $27.6 million. As per the information, the Q2 earnings report got here out yesterday.
- Healthcare Triangle HCTI inventory rose 13.63% to $3.75. The market worth of their excellent shares is at $19.2 million.
- Bausch Well being Firms BHC shares rose 13.18% to $8.5. The market worth of their excellent shares is at $2.7 billion.
- Replimune Group REPL shares elevated by 11.21% to $5.95. The market worth of their excellent shares is at $417.5 million.
Losers
- OneMedNet ONMD inventory decreased by 31.1% to $0.66 throughout Friday’s pre-market session. The corporate’s market cap stands at $44.3 million. As per the press launch, Q2 earnings got here out 2 days in the past.
- Cosciens Biopharma CSCI shares declined by 25.43% to $2.61. The corporate’s, Q2 earnings got here out yesterday.
- RenovoRx RNXT shares fell 23.39% to $0.95. The corporate’s market cap stands at $45.3 million. As per the information, the Q2 earnings report got here out yesterday.
- Encourage Veterinary IVP inventory fell 22.59% to $0.88. The corporate’s market cap stands at $2.9 million. The corporate’s, Q2 earnings got here out 2 days in the past.
- Tivic Well being Techniques TIVC shares declined by 17.15% to $2.9. The corporate’s market cap stands at $3.6 million. As per the information, the Q2 earnings report got here out yesterday.
- Sonoma Prescribed drugs SNOA inventory decreased by 13.1% to $4.58. The market worth of their excellent shares is at $8.6 million.
See Additionally: www.benzinga.com/cash/best-healthcare-stocks/
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.